CURE Epilepsy Funding: How Much Did They Raise & Key Investors

How Much Did CURE Epilepsy Raise?
Funding & Key Investors

CURE Epilepsy has solidified its position as a cornerstone of neurological research with a total capital accumulation of $440K. This latest financial milestone, characterized by a $290K injection, underscores the organization's capacity to sustain long-term, high-impact scientific inquiry. By securing this major strategic investment, the Chicago-based entity reinforces its commitment to accelerating the discovery of transformative therapies for those living with epilepsy.

The trajectory of this funding reflects a deliberate approach to scaling research initiatives. From its initial debt-based financing in 2020 to the subsequent capital infusion in 2021, CURE Epilepsy has demonstrated a consistent ability to attract the resources necessary to drive its mission forward in a competitive medical research landscape.

What is CURE Epilepsy?

CURE Epilepsy

Organizations

Non-Profit & Charitable Organizations

Founded in 1998, CURE Epilepsy operates as a specialized non-profit organization dedicated to the eradication of epilepsy through the promotion and funding of patient-focused research. Headquartered in Chicago, the organization bridges the gap between laboratory discovery and clinical application. By prioritizing high-risk, high-reward scientific projects that traditional funding bodies might overlook, CURE Epilepsy occupies a critical niche in the medical research ecosystem. Its operational model focuses on identifying and supporting the most promising research avenues that hold the potential to fundamentally alter the standard of care for patients worldwide.

How much funding has CURE Epilepsy raised?

CURE Epilepsy has raised a total of $440K across 2 funding rounds:

2020

Debt

$150K

2021

Debt

$290K

Debt (2020): $150K with participation from PPP

Debt (2021): $290K led by PPP

Key Investors in CURE Epilepsy

PPP

Public-Private Partnership

What's next for CURE Epilepsy?

With the successful acquisition of this latest round of financing, CURE Epilepsy is well-positioned to expand its portfolio of research grants and clinical partnerships. The organization is expected to leverage this capital to deepen its investment in cutting-edge neurological studies, potentially focusing on genetic markers and novel therapeutic interventions. As the entity moves into this next phase of growth, the focus will likely remain on translating research breakthroughs into tangible patient outcomes, thereby solidifying its influence in the global effort to cure epilepsy. The strategic deployment of these funds will be pivotal in maintaining the momentum of its ongoing research pipeline.

See full CURE Epilepsy company page

See More Financial Insights